Extracellular vesicles released by macrophages treated with the neuropeptides VIP and PACAP inhibited SARS-CoV-2 replication in monocytes and reduced the dangerous inflammatory response associated with severe COVID-19.
NF-κB BlockadeNeuropeptide-stimulated macrophage vesicles prevented the NF-κB activation that drives the dangerous inflammatory cascade in severe COVID-19
What the researchers found
Extracellular vesicles (EVs) from VIP- and PACAP-stimulated macrophages produced three key effects in SARS-CoV-2-infected monocytes: (1) inhibited viral RNA synthesis and replication, (2) protected cells from virus-induced cytopathic effects, and (3) reduced production of pro-inflammatory mediators. The anti-inflammatory mechanism worked through prevention of SARS-CoV-2-induced NF-κB activation.
Two distinct EV subpopulations were identified based on morphology: large EVs (LEV) and small EVs (SEV), both isolated by differential centrifugation from macrophages cultured for 24 hours in serum-reduced conditions. These findings reveal that neuropeptide-stimulated macrophage EVs possess immunoregulatory properties that could contribute to both antiviral and anti-inflammatory responses during COVID-19.
Why it matters
The 'cytokine storm' — an excessive inflammatory response driven largely by monocytes — is a major cause of death in severe COVID-19. This study reveals a natural neuropeptide-immune system communication pathway that can simultaneously fight the virus and calm the inflammation. Understanding how VIP and PACAP modulate macrophage signaling through extracellular vesicles could inform new therapeutic strategies for COVID-19 and other inflammatory viral infections.
How the study worked
Primary human monocyte-derived macrophages (MDM) were stimulated with the neuropeptides VIP and PACAP. Extracellular vesicles were isolated from culture medium by differential centrifugation and characterized morphologically into large and small EV subpopulations. These EVs were then applied to SARS-CoV-2-infected monocytes. Viral replication was measured by RNA quantification, cell viability by cytopathic effect assessment, inflammatory mediator production by relevant assays, and NF-κB activation by pathway analysis.
What this study cannot tell us
All experiments were conducted in vitro using primary human cells, not in living patients or animal models. The clinical relevance of these EV-mediated effects during actual COVID-19 infection is unknown. The specific cargo within the EVs responsible for antiviral and anti-inflammatory effects was not identified. Quantitative data on viral inhibition levels were not provided in the abstract. Translation of EV-based therapies to clinical use faces significant manufacturing and delivery challenges.
How to read the evidence
This is an in vitro laboratory study using primary human cells infected with SARS-CoV-2. While it provides mechanistic insights into neuropeptide-mediated immune regulation, no animal or human clinical testing was performed. This represents early-stage evidence of a potential therapeutic mechanism.
When this study was published
Published in 2024, this study contributes to the ongoing understanding of COVID-19 pathogenesis and neuropeptide immunology, building on the extensive SARS-CoV-2 research conducted since 2020.
The bigger picture
This study highlights an emerging area at the intersection of neuropeptide biology and innate immunity. VIP and PACAP are well-known immunomodulatory peptides, but this is among the first demonstrations that their effects can be transmitted between immune cells via extracellular vesicles. This cell-to-cell communication mechanism could have implications far beyond COVID-19, potentially applying to other inflammatory and infectious diseases where monocyte-driven inflammation plays a central role.
Questions still open
- What specific molecules within the neuropeptide-stimulated EVs are responsible for the antiviral and anti-inflammatory effects?
- Could VIP or PACAP administration directly to COVID-19 patients produce similar benefits by stimulating macrophage EV release in vivo?
- Do these neuropeptide-mediated EV effects extend to other respiratory viruses beyond SARS-CoV-2?
Common questions
What are VIP and PACAP, and why are they relevant to COVID-19?
What are extracellular vesicles and how do they fight infection?
Read the original research
Extracellular vesicles from primary human macrophages stimulated with VIP or PACAP mediate anti-SARS-CoV-2 activities in monocytes through NF-κB signaling pathway.
Microbes and infection, 26(8), 105400
Citation
Arteaga-Blanco, Luis A; Temerozo, Jairo R; Tiné, Lucas P S; Dantas-Pereira, Luíza; Sacramento, Carolina Q; Fintelman-Rodrigues, Natalia; Toja, Beatriz M; Gomes Dias, Suelen Silva; de Freitas, Caroline S; Espírito-Santo, Camila Couto; Silva, Ygor P; Frozza, Rudimar L; Bozza, Patrícia T; Menna-Barreto, Rubem F S; Souza, Thiago Moreno L; Bou-Habib, Dumith Chequer. (2024). Extracellular vesicles from primary human macrophages stimulated with VIP or PACAP mediate anti-SARS-CoV-2 activities in monocytes through NF-κB signaling pathway.. Microbes and infection, 26(8), 105400. https://doi.org/10.1016/j.micinf.2024.105400